-

Flatiron Health Enters New Five-Year Research Collaboration with FDA on Real-World Data

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its renewed collaboration with the Oncology Center of Excellence (OCE) of the United States Food and Drug Administration (FDA) to jointly develop and implement specific research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. The partnership will specifically evaluate RWD study designs and analytic methods through the collaborative development of priority, clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer.

“Flatiron is honored to continue our collaboration with FDA,” said Javier Jimenez, Chief Medical Officer, Flatiron Health. “Together we will explore the potential strengths and limitations of using real-world evidence through investigations of a broad set of research questions regarding the care and clinical outcomes of patients diagnosed with solid tumors and hematological malignancies.”

Further, projects under this collaboration will explore approaches to define and assess fit-for-purpose relevant data on treatment exposure, patient outcomes, and covariates required to answer specific questions of interest. As part of the research process, Flatiron’s datasets will be analyzed to explore fit for purpose RWD, create real-world study protocols using best pharmacoepidemiology practices, and conduct observational studies. Additionally, the collaboration will enable Flatiron to provide FDA access to their datasets/platform, and highlight their suite of services, including cutting-edge analytics, scientific expertise, and strategic consulting.

About Flatiron Health
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth

Contacts

Media:
Flatiron Health
Nina Toor
communications@flatiron.com

Flatiron Health

Details
Headquarters: New York, NY
CEO: Nathan Hubbard
Employees: 2,500
Organization: PRI

Release Versions

Contacts

Media:
Flatiron Health
Nina Toor
communications@flatiron.com

More News From Flatiron Health

NCCN and Flatiron Health Announce Renewal of Collaboration to Advance Real-World Data Research Across Leading Cancer Centers

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced the renewal of its collaboration with the National Comprehensive Cancer Network® (NCCN®), an alliance of leading cancer centers devoted to patient care, research, and education. The agreement, which dates back to 2014, extends through 2028 and reaffirms Flatiron's commitment to supporting real-world evidence (RWE) researc...

Flatiron Health Expands NSCLC Panoramic Dataset With Comprehensive Biomarker Data Model, Enabling Precision Medicine Research at Unprecedented Scale

NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced the expansion of its non-small cell lung cancer (NSCLC) Panoramic dataset with a comprehensive biomarker data model, delivering specimen-level molecular detail at a scale of 345,000+ patients across early and advanced settings. This expansion enables researchers to more deeply explore biomarker-driven treatment patterns, patien...

Flatiron Health Brings Three Research Acceptances to WCLC 2026

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the IASLC 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, with three research acceptances highlighting real-world evidence that advances precision medicine and treatment optimization in non-small cell lung cancer (NSCLC). The presentations demonstrate how Flatiron's high-quality, longitudinal data reveals clinical insights that shape oncology decision-making acro...
Back to Newsroom